{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T10:07:23Z","timestamp":1779530843254,"version":"3.53.1"},"reference-count":155,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Health Industry Research Project of Gansu Province","award":["GSWSKY2022-83"],"award-info":[{"award-number":["GSWSKY2022-83"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:p>Glioblastoma (GBM) is an extremely aggressive brain tumor for which there is currently no curative therapy available. The tumor microenvironment comprises an intricate interplay of various cells and molecules. Recent research has increasingly emphasized the inhibitory characteristics of the microenvironment, which significantly influence tumor growth, proliferation, and response to therapy through mechanisms including immunosuppression, hypoxia, and nutritional deficits. Comprehension of the crosstalk between GBM and the suppressive tumor microenvironment has the potential to advance future investigations aimed at surmounting this inhibitory microenvironment. Additionally, it could offer guidance for the formulation of novel therapeutic approaches. Significantly, we reviewed advanced therapeutic strategies to overcome GBM, such as immune checkpoint inhibitors, chimeric antigen receptor therapies, nanoparticles, small molecule inhibitors, and stem cell-based therapies. These strategies are continuously evolving and being improved, with the potential to significantly augment the therapeutic effectiveness against GBM.<\/jats:p>","DOI":"10.1097\/md.0000000000046285","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T22:01:46Z","timestamp":1764972106000},"page":"e46285","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Glioblastoma insights: Focus on crosstalk with the suppressive tumor microenvironment and advanced therapeutic strategies"],"prefix":"10.1097","volume":"104","author":[{"given":"Yi","family":"Wei","sequence":"first","affiliation":[{"name":"Neurosurgery Department, Gansu Provincial People\u2019s Hospital, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Shi","sequence":"additional","affiliation":[{"name":"Neurosurgery Department, Gansu Provincial People\u2019s Hospital, Lanzhou, China"},{"name":"Gansu University of Chinese Medicine, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Wang","sequence":"additional","affiliation":[{"name":"Neurosurgery Department, Gansu Provincial People\u2019s Hospital, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinwu","family":"Shang","sequence":"additional","affiliation":[{"name":"Neurosurgery Department, Gansu Provincial People\u2019s Hospital, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingwen","family":"Yu","sequence":"additional","affiliation":[{"name":"Neurosurgery Department, Gansu Provincial People\u2019s Hospital, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8476-3062","authenticated-orcid":false,"given":"Yunjuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Gansu Provincial People\u2019s Hospital, Lanzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260523","doi-asserted-by":"crossref","first-page":"0023","DOI":"10.34133\/bmr.0023","article-title":"Biomaterial-based CRISPR\/Cas9 delivery systems for tumor treatment.","volume":"28","author":"Li","year":"2024","journal-title":"Biomater Res"},{"key":"R2-20260523","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40824-023-00369-8","article-title":"Emerging biomaterials for tumor immunotherapy.","volume":"27","author":"Xiao","year":"2023","journal-title":"Biomater Res"},{"key":"R3-20260523","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12951-024-02298-7","article-title":"Exosome-based delivery strategies for tumor therapy: an update on modification, loading, and clinical application.","volume":"22","author":"Yang","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"R4-20260523","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ejca.2014.12.014","article-title":"Glioblastoma in England: 2007\u20132011.","volume":"51","author":"Brodbelt","year":"2015","journal-title":"Eur J Cancer"},{"issue":"Supplement_4","key":"R5-20260523","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016\u20132020.","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro-Oncology"},{"key":"R6-20260523","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"R7-20260523","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41392-023-01637-8","article-title":"From signalling pathways to targeted therapies: unravelling glioblastoma\u2019s secrets and harnessing two decades of progress.","volume":"8","author":"Dewdney","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R8-20260523","first-page":"299","article-title":"Management of glioblastoma: state of the art and future directions.","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R9-20260523","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jocn.2018.05.002","article-title":"Ten-year survival in glioblastoma. a systematic review.","volume":"54","author":"Tykocki","year":"2018","journal-title":"J Clin Neurosci"},{"key":"R10-20260523","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/annonc\/mdx169","article-title":"Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma.","volume":"28","author":"Qazi","year":"2017","journal-title":"Ann Oncol"},{"key":"R11-20260523","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.3390\/ijms19102879","article-title":"Glioblastoma chemoresistance: the double play by microenvironment and blood\u2013brain barrier.","volume":"19","author":"Da Ros","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R12-20260523","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12943-023-01818-7","article-title":"Immunotherapy: an emerging modality to checkmate brain metastasis.","volume":"22","author":"Ahmad","year":"2023","journal-title":"Mol Cancer"},{"key":"R13-20260523","first-page":"309","article-title":"Immunotherapy of cancer in 2012.","volume":"62","author":"Kirkwood","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"R14-20260523","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial.","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"key":"R15-20260523","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12943-023-01737-7","article-title":"NK cells are never alone: crosstalk and communication in tumour microenvironments.","volume":"22","author":"Zhou","year":"2023","journal-title":"Mol Cancer"},{"key":"R16-20260523","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3390\/cancers15051519","article-title":"Metabolic barriers to glioblastoma immunotherapy.","volume":"15","author":"Choudhary","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R17-20260523","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1042\/BST20180444","article-title":"Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments.","volume":"47","author":"Perrin","year":"2019","journal-title":"Biochem Soc Trans"},{"key":"R18-20260523","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13045-022-01358-5","article-title":"Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications.","volume":"15","author":"Zhong","year":"2022","journal-title":"J Hematol Oncol"},{"key":"R19-20260523","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41416-022-01864-w","article-title":"Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them.","volume":"127","author":"Habashy","year":"2022","journal-title":"Br J Cancer"},{"key":"R20-20260523","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41582-018-0025-8","article-title":"Multidimensional communication in the microenvirons of glioblastoma.","volume":"14","author":"Broekman","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"R21-20260523","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3390\/cells10092257","article-title":"The interplay between glioblastoma and its microenvironment.","volume":"10","author":"Dapash","year":"2021","journal-title":"Cells"},{"key":"R22-20260523","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.trecan.2022.04.010","article-title":"Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.","volume":"8","author":"Pang","year":"2022","journal-title":"Trends Cancer"},{"key":"R23-20260523","doi-asserted-by":"crossref","first-page":"732413","DOI":"10.1155\/2011\/732413","article-title":"Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.","volume":"2011","author":"Jackson","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"R24-20260523","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.3390\/cells10123529","article-title":"Glioblastoma: relationship between metabolism and immunosuppressive microenvironment.","volume":"10","author":"Hern\u00e1ndez","year":"2021","journal-title":"Cells"},{"key":"R25-20260523","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.it.2021.02.004","article-title":"Context-dependent glioblastoma\u2013macrophage\/microglia symbiosis and associated mechanisms.","volume":"42","author":"Xuan","year":"2021","journal-title":"Trends Immunol"},{"key":"R26-20260523","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","article-title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma.","volume":"31","author":"Wang","year":"2023","journal-title":"Mol Ther"},{"key":"R27-20260523","doi-asserted-by":"crossref","first-page":"e2111003119","DOI":"10.1073\/pnas.2111003119","article-title":"STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models.","volume":"119","author":"Berger","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"R28-20260523","doi-asserted-by":"crossref","first-page":"e141083","DOI":"10.1172\/JCI141083","article-title":"SLIT2\/ROBO signaling in tumor-associated microglia and macrophages drives glioblastoma immunosuppression and vascular dysmorphia.","volume":"131","author":"Geraldo","year":"2021","journal-title":"J Clin Invest"},{"key":"R29-20260523","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.neuron.2019.08.028","article-title":"Microglia\/brain macrophages as central drivers of brain tumor pathobiology.","volume":"104","author":"Gutmann","year":"2019","journal-title":"Neuron"},{"key":"R30-20260523","doi-asserted-by":"crossref","first-page":"26381","DOI":"10.1038\/srep26381","article-title":"Phenotypic dynamics of microglial and monocyte-derived cells in glioblastoma-bearing mice.","volume":"6","author":"Ricard","year":"2016","journal-title":"Sci Rep"},{"key":"R31-20260523","doi-asserted-by":"crossref","first-page":"964898","DOI":"10.3389\/fimmu.2022.964898","article-title":"Tumor-associated microglia and macrophages in glioblastoma: from basic insights to therapeutic opportunities.","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"R32-20260523","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1194637","article-title":"Fate mapping analysis reveals that adult microglia derive from primitive macrophages.","volume":"330","author":"Ginhoux","year":"2010","journal-title":"Science"},{"key":"R33-20260523","doi-asserted-by":"crossref","first-page":"e163446","DOI":"10.1172\/JCI163446","article-title":"Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy.","volume":"133","author":"Khan","year":"2023","journal-title":"J Clin Invest"},{"key":"R34-20260523","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1158\/0008-5472.CAN-16-2310","article-title":"Cellular and molecular identity of tumor-associated macrophages in glioblastoma.","volume":"77","author":"Chen","year":"2017","journal-title":"Cancer Res"},{"key":"R35-20260523","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.29379","article-title":"Resident microglia, and not peripheral macrophages, are the main source of brain tumor mononuclear cells.","volume":"137","author":"M\u00fcller","year":"2015","journal-title":"Int J Cancer"},{"key":"R36-20260523","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41593-020-00789-y","article-title":"Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization.","volume":"24","author":"Pombo Antunes","year":"2021","journal-title":"Nat Neurosci"},{"key":"R37-20260523","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/s41593-019-0532-y","article-title":"Mapping microglia states in the human brain through the integration of high-dimensional techniques.","volume":"22","author":"Sankowski","year":"2019","journal-title":"Nat Neurosci"},{"key":"R38-20260523","doi-asserted-by":"crossref","first-page":"14254","DOI":"10.1073\/pnas.1902366116","article-title":"Intravital 2-photon imaging reveals distinct morphology and infiltrative properties of glioblastoma-associated macrophages.","volume":"116","author":"Chen","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"R39-20260523","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12935-021-02089-2","article-title":"New insights into M1\/M2 macrophages: key modulators in cancer progression.","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int"},{"key":"R40-20260523","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines.","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"R41-20260523","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41590-022-01215-0","article-title":"Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression.","volume":"23","author":"Yeo","year":"2022","journal-title":"Nat Immunol"},{"key":"R42-20260523","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s41467-021-21407-w","article-title":"Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages.","volume":"12","author":"Ochocka","year":"2021","journal-title":"Nat Commun"},{"key":"R43-20260523","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.biomaterials.2018.01.053","article-title":"Hacking macrophage-associated immunosuppression for regulating glioblastoma angiogenesis.","volume":"161","author":"Cui","year":"2018","journal-title":"Biomaterials"},{"key":"R44-20260523","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/1568009616666160813191240","article-title":"Exploiting microglial functions for the treatment of glioblastoma.","volume":"17","author":"Dello Russo","year":"2017","journal-title":"Curr Cancer Drug Targets"},{"key":"R45-20260523","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00401-015-1529-6","article-title":"Resident microglia rather than peripheral macrophages promote vascularization in brain tumors and are source of alternative pro-angiogenic factors.","volume":"131","author":"Brandenburg","year":"2016","journal-title":"Acta Neuropathol"},{"key":"R46-20260523","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1073\/pnas.1721434116","article-title":"Microglia are effector cells of CD47-SIRP\u03b1 antiphagocytic axis disruption against glioblastoma.","volume":"116","author":"Hutter","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"R47-20260523","doi-asserted-by":"crossref","first-page":"e103790","DOI":"10.15252\/embj.2019103790","article-title":"Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment.","volume":"39","author":"Dumas","year":"2020","journal-title":"EMBO J"},{"key":"R48-20260523","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/s43018-023-00598-9","article-title":"Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response.","volume":"4","author":"Mei","year":"2023","journal-title":"Nat Cancer"},{"key":"R49-20260523","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41593-019-0370-y","article-title":"Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39.","volume":"22","author":"Takenaka","year":"2019","journal-title":"Nat Neurosci"},{"key":"R50-20260523","doi-asserted-by":"crossref","first-page":"12530","DOI":"10.1073\/pnas.0804273106","article-title":"Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion.","volume":"106","author":"Markovic","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"R51-20260523","first-page":"1533","article-title":"Oleanolic acid inhibits macrophage differentiation into the M2 phenotype and glioblastoma cell proliferation by suppressing the activation of STAT3.","volume":"26","author":"Fujiwara","year":"2011","journal-title":"Oncol Rep"},{"key":"R52-20260523","doi-asserted-by":"crossref","first-page":"1238233","DOI":"10.3389\/fimmu.2023.1238233","article-title":"The diversity and dynamics of tumor-associated macrophages in recurrent glioblastoma.","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"R53-20260523","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/neuonc\/nov245","article-title":"Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.","volume":"18","author":"Butowski","year":"2016","journal-title":"Neuro Oncol"},{"key":"R54-20260523","doi-asserted-by":"crossref","first-page":"eaaw7843","DOI":"10.1126\/scitranslmed.aaw7843","article-title":"Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance.","volume":"12","author":"Akkari","year":"2020","journal-title":"Sci Transl Med"},{"key":"R55-20260523","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","article-title":"Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade.","volume":"32","author":"Saha","year":"2017","journal-title":"Cancer Cell"},{"key":"R56-20260523","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","article-title":"Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy.","volume":"21","author":"Wu","year":"2022","journal-title":"Mol Cancer"},{"key":"R57-20260523","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40364-021-00333-5","article-title":"Landscape of myeloid-derived suppressor cell in tumor immunotherapy.","volume":"9","author":"Hao","year":"2021","journal-title":"Biomarker Res"},{"key":"R58-20260523","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/neuonc\/nor042","article-title":"Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma.","volume":"13","author":"Raychaudhuri","year":"2011","journal-title":"Neuro-Oncology"},{"key":"R59-20260523","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/neuonc\/now034","article-title":"Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8\/9 and arginase and suppress T cell function.","volume":"18","author":"Gielen","year":"2016","journal-title":"Neuro-Oncology"},{"key":"R60-20260523","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/neuonc\/nov280","article-title":"CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.","volume":"18","author":"Dubinski","year":"2016","journal-title":"Neuro-Oncology"},{"key":"R61-20260523","doi-asserted-by":"crossref","first-page":"e122264","DOI":"10.1172\/jci.insight.122264","article-title":"Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis.","volume":"3","author":"Alban","year":"2018","journal-title":"JCI Insight"},{"key":"R62-20260523","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3390\/cells10040893","article-title":"New insights into the multifaceted role of myeloid-derived suppressor cells (MDSCs) in high-grade gliomas: from metabolic reprograming, immunosuppression, and therapeutic resistance to current strategies for targeting MDSCs.","volume":"10","author":"Lakshmanachetty","year":"2021","journal-title":"Cells"},{"key":"R63-20260523","doi-asserted-by":"crossref","first-page":"8844313","DOI":"10.1155\/2020\/8844313","article-title":"Explicating the pivotal pathogenic, diagnostic, and therapeutic biomarker potentials of myeloid-derived suppressor cells in glioblastoma.","volume":"2020","author":"Richard","year":"2020","journal-title":"Dis Markers"},{"key":"R64-20260523","doi-asserted-by":"crossref","first-page":"47","DOI":"10.15698\/cst2019.02.176","article-title":"Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma.","volume":"3","author":"Won","year":"2019","journal-title":"Cell Stress"},{"key":"R65-20260523","doi-asserted-by":"crossref","first-page":"e130748","DOI":"10.1172\/jci.insight.130748","article-title":"Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells.","volume":"4","author":"Peereboom","year":"2019","journal-title":"JCI Insight"},{"key":"R66-20260523","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1158\/1078-0432.CCR-23-0203","article-title":"Bavituximab decreases immunosuppressive myeloid-derived suppressor cells in newly diagnosed glioblastoma patients.","volume":"29","author":"Ly","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R67-20260523","doi-asserted-by":"crossref","first-page":"993444","DOI":"10.3389\/fimmu.2022.993444","article-title":"Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2(+)\/CX3CR1(+) M-MDSCs into the tumor microenvironment in a redundant manner.","volume":"13","author":"Takacs","year":"2022","journal-title":"Front Immunol"},{"key":"R68-20260523","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1021\/acsnano.1c07492","article-title":"Systemic delivery of an adjuvant CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy.","volume":"16","author":"Alghamri","year":"2022","journal-title":"ACS Nano"},{"key":"R69-20260523","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","article-title":"Neutrophil diversity and plasticity in tumour progression and therapy.","volume":"20","author":"Jaillon","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"R70-20260523","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-021-01187-y","article-title":"Neutrophils in cancer carcinogenesis and metastasis.","volume":"14","author":"Xiong","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R71-20260523","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil phenotype by TGF-beta: \u201cN1\u201d versus \u201cN2\u201d TAN.","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"R72-20260523","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s004010051093","article-title":"Neutrophil infiltration into human gliomas.","volume":"98","author":"Fossati","year":"1999","journal-title":"Acta Neuropathol"},{"key":"R73-20260523","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1158\/1078-0432.CCR-13-1279","article-title":"Neutrophils promote the malignant glioma phenotype through S100A4.","volume":"20","author":"Liang","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R74-20260523","doi-asserted-by":"crossref","first-page":"e1075693","DOI":"10.1080\/2162402X.2015.1075693","article-title":"Enhanced neutrophil activity is associated with shorter time to tumor progression in glioblastoma patients.","volume":"5","author":"Rahbar","year":"2016","journal-title":"Oncoimmunology"},{"key":"R75-20260523","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1016\/j.cell.2023.08.043","article-title":"The local microenvironment drives activation of neutrophils in human brain tumors.","volume":"186","author":"Maas","year":"2023","journal-title":"Cell"},{"key":"R76-20260523","doi-asserted-by":"crossref","first-page":"1183465","DOI":"10.3389\/fimmu.2023.1183465","article-title":"Tumor-neutrophil crosstalk promotes in vitro and in vivo glioblastoma progression.","volume":"14","author":"Rubenich","year":"2023","journal-title":"Front Immunol"},{"key":"R77-20260523","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1038\/s41467-020-19193-y","article-title":"Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression.","volume":"11","author":"Yee","year":"2020","journal-title":"Nat Commun"},{"key":"R78-20260523","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1007\/s11064-017-2378-6","article-title":"Anti-glioma activity of dapsone and its enhancement by synthetic chemical modification.","volume":"42","author":"Karpel-Massler","year":"2017","journal-title":"Neurochem Res"},{"key":"R79-20260523","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jconrel.2023.08.020","article-title":"Inflammatory responsive neutrophil-like membrane-based drug delivery system for post-surgical glioblastoma therapy.","volume":"362","author":"Chen","year":"2023","journal-title":"J Control Release"},{"key":"R80-20260523","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41467-023-37872-4","article-title":"CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy.","volume":"14","author":"Chang","year":"2023","journal-title":"Nat Commun"},{"key":"R81-20260523","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41467-023-37361-8","article-title":"Monocyte depletion enhances neutrophil influx and proneural to mesenchymal transition in glioblastoma.","volume":"14","author":"Chen","year":"2023","journal-title":"Nat Commun"},{"key":"R82-20260523","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-023-01714-0","article-title":"Regulatory cells and the effect of cancer immunotherapy.","volume":"22","author":"Iglesias-Escudero","year":"2023","journal-title":"Mol Cancer"},{"key":"R83-20260523","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1158\/1078-0432.CCR-08-0320","article-title":"Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas.","volume":"14","author":"Heimberger","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R84-20260523","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/neuonc\/nos014","article-title":"Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy.","volume":"14","author":"Crane","year":"2012","journal-title":"Neuro-Oncology"},{"key":"R85-20260523","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3389\/fimmu.2020.00835","article-title":"Single-cell atlas reveals complexity of the immunosuppressive microenvironment of initial and recurrent glioblastoma.","volume":"11","author":"Fu","year":"2020","journal-title":"Front Immunol"},{"key":"R86-20260523","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.4161\/epi.22675","article-title":"Epigenetic biomarkers of T-cells in human glioma.","volume":"7","author":"Wiencke","year":"2012","journal-title":"Epigenetics"},{"key":"R87-20260523","doi-asserted-by":"crossref","first-page":"e32614","DOI":"10.1371\/journal.pone.0032614","article-title":"Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients.","volume":"7","author":"Fong","year":"2012","journal-title":"PLoS One"},{"key":"R88-20260523","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00262-007-0336-x","article-title":"Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.","volume":"57","author":"Jordan","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"R89-20260523","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jneuroim.2010.05.020","article-title":"Prognostic significance and mechanism of Treg infiltration in human brain tumors.","volume":"225","author":"Jacobs","year":"2010","journal-title":"J Neuroimmunol"},{"key":"R90-20260523","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1158\/0008-5472.CAN-16-0144","article-title":"CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory t cells and myeloid-derived suppressor cells.","volume":"76","author":"Chang","year":"2016","journal-title":"Cancer Res"},{"key":"R91-20260523","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects.","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"R92-20260523","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.clineuro.2013.12.004","article-title":"The role of regulatory T-cells in glioma immunology.","volume":"119","author":"Ooi","year":"2014","journal-title":"Clin Neurol Neurosurg"},{"key":"R93-20260523","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s43018-023-00547-6","article-title":"CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma.","volume":"4","author":"van Hooren","year":"2023","journal-title":"Nat Cancer"},{"key":"R94-20260523","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1158\/0008-5472.CAN-19-1577","article-title":"Dysregulation of glutamate transport enhances treg function that promotes vegf blockade resistance in glioblastoma.","volume":"80","author":"Long","year":"2020","journal-title":"Cancer Res"},{"issue":"15_suppl","key":"R95-20260523","doi-asserted-by":"crossref","first-page":"e13518","DOI":"10.1200\/JCO.2016.34.15_suppl.e13518","article-title":"Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).","volume":"34","author":"Vlahovic","year":"2016","journal-title":"J Clin Oncol"},{"key":"R96-20260523","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/s43018-020-00133-0","article-title":"CD25-T(reg)-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.","volume":"1","author":"Solomon","year":"2020","journal-title":"Nat Cancer"},{"key":"R97-20260523","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc704","article-title":"Hypoxia \u2013 a key regulatory factor in tumour growth.","volume":"2","author":"Harris","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"R98-20260523","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.3390\/cancers15092613","article-title":"The role of hypoxia and cancer stem cells in development of glioblastoma.","volume":"15","author":"Shi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R99-20260523","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41419-023-05663-w","article-title":"Glioblastoma upregulates SUMOylation of hnRNP A2\/B1 to eliminate the tumor suppressor miR-204-3p, accelerating angiogenesis under hypoxia.","volume":"14","author":"Guo","year":"2023","journal-title":"Cell Death Dis"},{"key":"R100-20260523","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1631\/jzus.B2200269","article-title":"Hypoxia-induced ROS aggravate tumor progression through HIF-1\u03b1-SERPINE1 signaling in glioblastoma.","volume":"24","author":"Zhang","year":"2023","journal-title":"J Zhejiang Univ Sci B"},{"key":"R101-20260523","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41388-022-02542-0","article-title":"Hypoxia-induced circADAMTS6 in a TDP43-dependent manner accelerates glioblastoma progression via ANXA2\/ NF-\u03baB pathway.","volume":"42","author":"Zhao","year":"2023","journal-title":"Oncogene"},{"key":"R102-20260523","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1158\/0008-5472.CAN-15-2058","article-title":"FGFR1 induces glioblastoma radioresistance through the PLC\u03b3\/Hif1\u03b1 pathway.","volume":"76","author":"Gouaz\u00e9-Andersson","year":"2016","journal-title":"Cancer Res"},{"key":"R103-20260523","doi-asserted-by":"crossref","first-page":"1614336","DOI":"10.1155\/2022\/1614336","article-title":"Hypoxia-driven M2-polarized macrophages facilitate cancer aggressiveness and temozolomide resistance in glioblastoma.","volume":"2022","author":"Zhang","year":"2022","journal-title":"Oxid Med Cell Longevity"},{"key":"R104-20260523","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/neuonc\/noaa265","article-title":"Nestin+\/CD31+ cells in the hypoxic perivascular niche regulate glioblastoma chemoresistance by upregulating JAG1 and DLL4.","volume":"23","author":"Zheng","year":"2021","journal-title":"Neuro-Oncology"},{"key":"R105-20260523","doi-asserted-by":"crossref","first-page":"782043","DOI":"10.3389\/fonc.2021.782043","article-title":"Hypoxia contributes to poor prognosis in primary IDH-wt GBM by inducing tumor cells MES-like transformation trend and inhibiting immune cells activity.","volume":"11","author":"Xiong","year":"2021","journal-title":"Front Oncol"},{"key":"R106-20260523","doi-asserted-by":"crossref","first-page":"104720","DOI":"10.1016\/j.phrs.2020.104720","article-title":"Intercellular crosstalk of hepatic stellate cells in liver fibrosis: new insights into therapy.","volume":"155","author":"Cai","year":"2020","journal-title":"Pharmacol Res"},{"key":"R107-20260523","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1101\/gad.261982.115","article-title":"Cancer stem cells in glioblastoma.","volume":"29","author":"Lathia","year":"2015","journal-title":"Genes Dev"},{"key":"R108-20260523","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","article-title":"Brain immunology and immunotherapy in brain tumours.","volume":"20","author":"Sampson","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"R109-20260523","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3390\/cancers14051176","article-title":"Current understanding of hypoxia in glioblastoma multiforme and its response to immunotherapy.","volume":"14","author":"Park","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R110-20260523","doi-asserted-by":"crossref","first-page":"12608","DOI":"10.3390\/ijms222212608","article-title":"Hypoxia: the cornerstone of glioblastoma.","volume":"22","author":"Dom\u00e8nech","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R111-20260523","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","article-title":"Cancer metabolism: looking forward.","volume":"21","author":"Mart\u00ednez-Reyes","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"R112-20260523","doi-asserted-by":"crossref","first-page":"683276","DOI":"10.3389\/fcell.2021.683276","article-title":"Metabolic drivers of invasion in glioblastoma.","volume":"9","author":"Garcia","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"R113-20260523","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1084\/jem.20101470","article-title":"Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme.","volume":"208","author":"Wolf","year":"2011","journal-title":"J Exp Med"},{"key":"R114-20260523","doi-asserted-by":"crossref","first-page":"8872977","DOI":"10.1155\/2021\/8872977","article-title":"A novel glucose metabolism-related gene signature for overall survival prediction in patients with glioblastoma.","volume":"2021","author":"Zhang","year":"2021","journal-title":"Biomed Res Int"},{"key":"R115-20260523","doi-asserted-by":"crossref","first-page":"e0123544","DOI":"10.1371\/journal.pone.0123544","article-title":"Comprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastoma.","volume":"10","author":"Sanzey","year":"2015","journal-title":"PLoS One"},{"key":"R116-20260523","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2013.04.005","article-title":"Metabolic pathways in immune cell activation and quiescence.","volume":"38","author":"Pearce","year":"2013","journal-title":"Immunity"},{"key":"R117-20260523","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment.","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"key":"R118-20260523","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune Checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance.","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"R119-20260523","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial.","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro-Oncology"},{"key":"R120-20260523","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro-Oncology"},{"key":"R121-20260523","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/s43018-021-00260-2","article-title":"ERK1\/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.","volume":"2","author":"Arrieta","year":"2021","journal-title":"Nat Cancer"},{"key":"R122-20260523","first-page":"454","article-title":"Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.","volume":"19","author":"Roth","year":"2017","journal-title":"Neuro-Oncology"},{"key":"R123-20260523","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat Med"},{"key":"R124-20260523","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","article-title":"Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.","volume":"25","author":"Schalper","year":"2019","journal-title":"Nat Med"},{"key":"R125-20260523","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey.","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat Med"},{"key":"R126-20260523","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.3390\/cells12131770","article-title":"Chimeric antigen receptor T Cells in glioblastoma-current concepts and promising future.","volume":"12","author":"Kringel","year":"2023","journal-title":"Cells"},{"key":"R127-20260523","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3390\/cancers15041249","article-title":"CAR-T Therapy in GBM: current challenges and avenues for improvement.","volume":"15","author":"Pant","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R128-20260523","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-Cell therapy.","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"key":"R129-20260523","doi-asserted-by":"crossref","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"R130-20260523","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","article-title":"Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma.","volume":"24","author":"Brown","year":"2022","journal-title":"Neuro-Oncology"},{"key":"R131-20260523","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial.","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol"},{"key":"R132-20260523","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12943-022-01672-z","article-title":"NK cells and solid tumors: therapeutic potential and persisting obstacles.","volume":"21","author":"Tong","year":"2022","journal-title":"Mol Cancer"},{"key":"R133-20260523","doi-asserted-by":"crossref","first-page":"1192128","DOI":"10.3389\/fonc.2023.1192128","article-title":"CAR-NK cell therapy for glioblastoma: what to do next?","volume":"13","author":"Xiong","year":"2023","journal-title":"Front Oncol"},{"key":"R134-20260523","doi-asserted-by":"crossref","first-page":"djv375","DOI":"10.1093\/jnci\/djv375","article-title":"ErbB2\/HER2-specific NK cells for targeted therapy of glioblastoma.","volume":"108","author":"Zhang","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"R135-20260523","doi-asserted-by":"crossref","first-page":"11483","DOI":"10.1038\/srep11483","article-title":"CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells.","volume":"5","author":"Han","year":"2015","journal-title":"Sci Rep"},{"key":"R136-20260523","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s13402-023-00842-5","article-title":"Therapeutic effects against high-grade glioblastoma mediated by engineered induced neural stem cells combined with GD2-specific CAR-NK.","volume":"46","author":"Liu","year":"2023","journal-title":"Cell Oncol (Dordr)"},{"key":"R137-20260523","doi-asserted-by":"crossref","first-page":"e2107507118","DOI":"10.1073\/pnas.2107507118","article-title":"Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells.","volume":"118","author":"Wang","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"R138-20260523","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood\u2013brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro-Oncology"},{"key":"R139-20260523","doi-asserted-by":"crossref","first-page":"103008","DOI":"10.1016\/j.cis.2023.103008","article-title":"Emerging strategies to fabricate polymeric nanocarriers for enhanced drug delivery across blood\u2013brain barrier: an overview.","volume":"320","author":"Song","year":"2023","journal-title":"Adv Colloid Interface Sci"},{"key":"R140-20260523","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1038\/s41467-020-19225-7","article-title":"Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy.","volume":"11","author":"Gregory","year":"2020","journal-title":"Nat Commun"},{"key":"R141-20260523","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.nano.2018.01.021","article-title":"Enhancing glioblastoma treatment using cisplatin-gold-nanoparticle conjugates and targeted delivery with magnetic resonance-guided focused ultrasound.","volume":"14","author":"Coluccia","year":"2018","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"R142-20260523","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jconrel.2022.07.023","article-title":"Polymeric nanoparticles for drug delivery in glioblastoma: state of the art and future perspectives.","volume":"349","author":"Madani","year":"2022","journal-title":"J Control Release"},{"key":"R143-20260523","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.7150\/thno.82005","article-title":"Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment.","volume":"13","author":"Iturrioz-Rodr\u00edguez","year":"2023","journal-title":"Theranostics"},{"key":"R144-20260523","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.apsb.2021.12.019","article-title":"Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds.","volume":"12","author":"Liu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"R145-20260523","doi-asserted-by":"crossref","first-page":"911876","DOI":"10.3389\/fonc.2022.911876","article-title":"Small molecule inhibitors in adult high-grade glioma: from the past to the future.","volume":"12","author":"Huang","year":"2022","journal-title":"Front Oncol"},{"key":"R146-20260523","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/neuonc\/noad092","article-title":"Cell-based therapies for glioblastoma: promising tools against tumor heterogeneity.","volume":"25","author":"Nehama","year":"2023","journal-title":"Neuro-Oncology"},{"key":"R147-20260523","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1021\/acs.nanolett.8b04697","article-title":"Engineered mesenchymal stem cell\/nanomedicine spheroid as an active drug delivery platform for combinational glioblastoma therapy.","volume":"19","author":"Suryaprakash","year":"2019","journal-title":"Nano Lett"},{"key":"R148-20260523","doi-asserted-by":"crossref","first-page":"11120","DOI":"10.1021\/acs.nanolett.3c03516","article-title":"Cell membrane-coated oncolytic adenovirus for targeted treatment of glioblastoma.","volume":"23","author":"Jia","year":"2023","journal-title":"Nano Lett"},{"key":"R149-20260523","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1021\/acs.molpharmaceut.9b00104","article-title":"Exosomes as drug carriers for cancer therapy.","volume":"16","author":"Pullan","year":"2019","journal-title":"Mol Pharm"},{"key":"R150-20260523","doi-asserted-by":"crossref","first-page":"CNS73","DOI":"10.2217\/cns-2020-0026","article-title":"Stem cells for the treatment of glioblastoma: a 20-year perspective.","volume":"10","author":"Calinescu","year":"2021","journal-title":"CNS Oncol"},{"key":"R151-20260523","doi-asserted-by":"crossref","first-page":"406","DOI":"10.5483\/BMBRep.2018.51.8.105","article-title":"Exosomes derived from microRNA-584 transfected mesenchymal stem cells: novel alternative therapeutic vehicles for cancer therapy.","volume":"51","author":"Kim","year":"2018","journal-title":"BMB Rep"},{"key":"R152-20260523","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s13287-022-03212-4","article-title":"Mesenchymal stem cell-derived exosomes as a new therapeutic strategy in the brain tumors.","volume":"13","author":"Ghasempour","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"R153-20260523","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/s13287-021-02629-7","article-title":"Mesenchymal stem cells-derived exosomes for drug delivery.","volume":"12","author":"Sun","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"R154-20260523","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jconrel.2022.03.036","article-title":"Heme Oxygenase-1 targeting exosomes for temozolomide resistant glioblastoma synergistic therapy.","volume":"345","author":"Rehman","year":"2022","journal-title":"J Control Release"},{"key":"R155-20260523","doi-asserted-by":"crossref","first-page":"18327","DOI":"10.1021\/acsnano.1c07587","article-title":"A microfluidics-based scalable approach to generate extracellular vesicles with enhanced therapeutic microrna loading for intranasal delivery to mouse glioblastomas.","volume":"15","author":"Wang","year":"2021","journal-title":"ACS Nano"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T10:02:39Z","timestamp":1779530559000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":155,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046285","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"2024-07-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}